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Weir et al S38.e2Background: Invasive melanoma of the skin is the third most common cancer diagnosed among
adolescents and young adults (aged 15-39 years) in the United States. Understanding the burden of
melanoma in this age group is important to identifying areas for etiologic research and in developing
effective prevention approaches aimed at reducing melanoma risk.Methods: Melanoma incidence data reported from 38 National Program of Cancer Registries and/or
Surveillance Epidemiology and End Results statewide cancer registries covering nearly 67.2% of the US
population were used to estimate age-adjusted incidence rates for persons 15-39 years of age. Incidence
rate ratios were calculated to compare rates between demographic groups.Results: Melanoma incidence was higher among females (age-adjusted incidence rates = 9.74; 95%
confidence interval 9.62-9.86) compared with males (age-adjusted incidence rates = 5.77; 95% confidence
interval 5.68-5.86), increased with age, and was higher in non-Hispanic white compared with Hispanic
white and black, American Indians/Alaskan Natives, and Asian and Pacific Islanders populations.
Melanoma incidence rates increased with year of diagnosis in females but not males. The majority of
melanomas were diagnosed on the trunk in all racial and ethnic groups among males but only in non-
Hispanic whites among females. Most melanomas were diagnosed at localized stage, and among those
melanomas with known histology, the majority were superficial spreading.Limitations: Accuracy of melanoma cases reporting was limited because of some incompleteness
(delayed reporting) or nonspecific reporting including large proportion of unspecified histology.Conclusions: Differences in incidence rates by anatomic site, histology, and stage among adolescents and
young adults by race, ethnicity, and sex suggest that both host characteristics and behaviors influence risk.
These data suggest areas for etiologic research around gene-environment interactions and the need for
targeted cancer control activities specific to adolescents and young adult populations. ( J Am Acad
Dermatol 2011;65:S38.e1-13.)
Keywords: adolescents; cancer; incidence; melanoma; National Program of Cancer Registries; surveillance;
Surveillance Epidemiology and End Results; young adults.Cutaneous melanoma (hereafter called mela-
noma) is the second most commonly diagnosed
cancer (after lymphomas) and the most lethal form
of skin cancer among adolescents and young adults
under the age of 30 years in the United States.1
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S38.e3 Weir et alPrimary melanoma evolves from melanocyte
transformation directly or in precursor lesions.
Melanoma tumorigenesis likely represents a multi-
step process involving accumulation of sequential
genetic alterations.10 The major modifiable risk fac-
tor for melanoma is overexposure to ultraviolet (UV)
radiation (UVR), particularly intermittent exposure,CAPSULE SUMMARY
d Melanoma is the third most commonly
diagnosed cancer among adolescents
and young adults (aged 15-39 years) in
the United States.
d Understanding the burden of melanoma
in this age group is important to
identifying areas for etiologic research
and in developing effective prevention
approaches aimed at reducing
melanoma risk.
d This study, using National Program of
Cancer Registries/Surveillance
Epidemiology and End Results combined
incidence data, describes the burden of
invasive melanoma of the skin in
adolescents and young adults in the
United States by demographic and
tumor characteristics.whether from sunlight or ar-
tificial sources.11 Adolescents
and young adults appear to
be at particular risk for de-
veloping melanoma because
of these exposures early in
life.12,13
Other factors consistently
shown to confer an increased
risk of developingmelanoma
include a family history of
melanoma, tendency to de-
velop freckles, light hair
color, immunosuppression,
and a higher number of
nevi.14,15 Perhaps the most
distinct risk factor forpediatric
melanoma is its relationship
with pre-existing melanocytic
nevi.16,17 Melanoma is rare
among darkly pigmented eth-
nic groups relative to whites.
This presumably relates to the
higher sensitivity of white
skin to UVR exposure. Of all racial groups in the
United States, whites have the highest incidence rates
of melanoma regardless of age.18
Understanding the burden and risk of melanoma
among adolescents and young adults is important to
identify areas for etiologic research and to develop
effective cancer control activities aimed at reducing
melanoma incidence and deaths in this age group.
However, incidence patterns by racial and ethnic
subgroups within this population have not been
well described in the United States because of
incomplete surveillance coverage. Through the com-
bined efforts of the two federal cancer surveillance
programs, the Centers for Disease Control and
Prevention’s National Program of Cancer Registries
(NPCR) and the National Cancer Institute’s (NCI)
Surveillance Epidemiology and End Results (SEER)
Program, there are now population-based cancer
registries operating in all states and the District of
Columbia.19,20 The combined coverage of the two
federal programs allows us to better monitor the
burden of cancer in racially, ethnically, and geo-
graphically diverse populations throughout the
United States.18In this analysis we examined the burden of
melanoma in adolescents and young adults be-
tween the ages of 15 to 39 years diagnosed
between 1999 and 2006 by demographic and tumor
characteristics.METHODS
Detailed descriptions of
the data sources and
methods used for evaluation
and analysis of these data are
found in another article in
this supplement.21 A brief
description of the data sour-
ces and methods is included
herein.
Cancer cases
Cancer incidence data for
the period 1999 through
2006 for individuals aged 15
to 39 years at diagnosis and
covering 67.2% of the US
population were obtained
from 38 statewide cancer
registries that participate in
either or both NPCR and
SEER. Data were collected
and reported by use of stan-
dards established by theNorth American Association of Central Cancer
Registries.22
Primary site and histologywere coded according to
the International Classification ofDiseaseseOncology
(ICD-O) edition in use at the time of diagnosis and
converted to the third edition (ICD-O-3).23 Incident
cases of invasive melanoma of the skin (defined as
ICD-O-3 site codes C440-449 and histology codes
8720-8790) were selected and categorized according
toanatomicbody sites: face, head, andneck, including
skin of lips, eyelids, ears, scalp, and neck (C44.0-
C44.4); trunk, including back, abdomen, and chest
(C44.5); upper extremities, including shoulders
(C44.6); lower extremities, including hips (C44.7);
and overlapping sites and not otherwise specified
(NOS) (C44.8-C44.9). Among microscopically con-
firmed melanoma cases, histopathologic types were
categorized as follows: superficial spreading (ICD-O-3
code 8743); nodular (ICD-O-3 code 8721); lentigo
maligna (ICD-O-3 code 8742); acral lentiginous (ICD-
O-3 code 8744); melanoma NOS (Histology NOS)
(ICD-O-3 code 8720); and all other specified histolo-
gies (other specified) between ICD-O-3 8722 to 8780
and not previously listed. Beginning in 2004, cancer
Abbreviations used:
AI/AN: American Indians/Alaskan Natives
API: Asian Pacific Islanders
CI: confidence interval
HW: Hispanic white
ICD-O: International Classification of
DiseaseseOncology
ICD-O-
3:
International Classification of Disease-
seOncology, Third Edition
NCI: National Cancer Institute
NHW: non-Hispanic white
NOS: not otherwise specified
NPCR: National Program of Cancer Registries
IRR: incidence rate ratio
SEER: Surveillance Epidemiology and End
Results
UV: ultraviolet
UVR: ultraviolet radiation
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ing stage data according to the online Collaborative
Staging coding instructions.24 For cases diagnosed
between2004and2006, theCollaborative Stagingdata
were recoded intoDerived SEER Summary Stage 2000:
localized, regional, distant, unknown, and NOS.25
Because of the change in staging scheme, stage
analyses were limited to diagnosis years 2004 through
2006 to ensure consistency.
Population data
County level population estimates produced by
the US Census Bureau and bridged to single-race
estimates were used as denominators in the rate
calculations. The NCI made further refinements re-
garding race and county geographic codes and
provided public access to these population
estimates.26
Hispanic ethnicity is not mutually exclusive from
race (Table I). Using race and ethnicity data, the
following categories were created: non-Hispanic
white (NHW); Hispanic white (HW); black, including
non-Hispanic and Hispanic; American Indians/
Alaskan Natives (AI/AN) including non-Hispanic
and Hispanic; and Asian Pacific Islanders (API)
including non-Hispanic and Hispanic. A combined
category of black, AI/AN, and API (non-white) was
constructed for analyses examining race and ethnic-
ity by site and histology because case counts for
populations other than NHW and HW were small.
Other unspecified and unknown race categories
were combined.
Analyses
Frequencies, percent distributions and averaged
annual age-adjusted incidence rates per 100,000
population were calculated by use of SEER*Stat
software (V6.6.2, National Cancer Institute,
Bethesda, Maryland).27 Rates were adjusted to the2000 US standard population by use of 5-year age
groups (15-19, 20-24, 25-29, 30-34, and 35-39 years).
Standard errors (SE) and 95% confidence intervals
(CI) were constructed by use of the modified gamma
method to ensure proper coverage for small case
counts, low incidence rates, and populations with
age distributions that differ from the standard age
distribution.28 Rates based on counts of less than 16
cases for the entire diagnosis period (1999-2006)
were suppressed. P values and 95% CI for incidence
rate ratios (IRR) were calculated for the purpose of
comparing incidence rates between populations.29
Reported IRR are based on findings where the IRR
was statistically significantly different from 1 (2-sided
P\ .05).
Rates were not constructed for other unspecified
and unknown racial groups because corresponding
population data were not available. Case counts
greater than 1 but less than 16 were suppressed for
the distribution of incident cases in the tables but
were included in the graphical representation of the
distribution of incident cases.
RESULTS
Demographic characteristics
A total of 361,394 invasive cancers were diag-
nosed among adolescents and young adults aged 15
to 39 years during 1999 through 2006. Melanomawas
the third most common cancer diagnosed behind
lymphoma and breast cancer. Of the 41,715 invasive
melanomas reported (Table I); 15,677 were diag-
nosed in males (37.6%) and 26,036 in females
(62.4%). Greater than 92% of cases were diagnosed
among NHW and HW males and females. Less than
1% of cases were diagnosed among blacks, AI/AN, or
API. Between 5 and 6% of cases were reported with
unknown race.
The risk of being given a diagnosis of melanoma
was greater in females compared with males (IRR =
1.69; 95% CI 1.65-1.72) (Table II). Age-adjusted
incidence rates were higher in females compared
with males in every age, diagnosis year, race, and
ethnicity group examined. The relative risk of being
given a diagnosis of melanoma increased at least
7-fold between the ages of 15 to 19 years and 35 to 39
years among males and females (RR = 7.97; 95% CI
7.40-8.60 and IRR = 7.06; 95% CI 6.65-7.51, respec-
tively). Among females, the incidence rate increased
in each subsequent calendar period from 8.85 per
100,000 in 1999 through 2000 to 10.31 per 100,000 in
2004 through 2006. Risk did not increase with
calendar period among males. Melanoma incidence
was significantly higher among NHW males (7.94/
100,000) and females (13.23/100,000) followed in
order of magnitude by AI/AN, HW, API, and blacks.
Table I. Invasive melanoma incident cases among adolescents and young adults (age 15-39 years) by race and
ethnicity: United States 1999 through 2006
Male (n = 15,677) Female (n = 26,036)
Non-Hispanic Hispanic Non-Hispanic Hispanic
White 14,191 (93.0%) 392 (93.8%) 23,321 (92.8%) 853 (93.7%)
Black 79 (0.5%) e 125 (0.5%) e
AI/AN 53 (0.4%) e 74 (0.3%) e
API 64 (0.4%) e 117 (0.5%) e
Other unspecified and unknown 872 (5.7%) 22 (5.3%) 1489 (5.9%) 48 (5.3%)
All races 15,259 418 25,126 910
Case counts[1 and\16 cases were suppressed.
Data are from population-based cancer registries that participate in National Program of Cancer Registries and/or Surveillance Epidemiology
and End Results Program and meet high-quality data criteria. These registries cover 67.2% of population for 1999-2006.
AI/AN, American Indian/Alaskan Natives, API, Asian and Pacific Islander.
Table II. Invasive melanoma incidence among adolescents and young adults (age 15-39 years) by
demographic characteristics: United States 1999 through 2006
Sex No. Rate 95% CI IRR 95% CI
Male 15,677 5.77 5.68-5.86 1.00 e
Female 26,036 9.74 9.62-9.86 1.69* 1.65-1.72
Age, y
Male Female
No. Rate (SE) IRR 95% CI No. Rate (SE) IRR 95% CI
15-19 783 1.39 (0.05) 1.00 e 1191 2.23 (0.06) 1.00 e
20-24 1539 2.80 (0.07) 2.01* 1.85-2.20 3318 6.38 (0.11) 2.86* 2.68-3.06
25-29 2642 5.03 (0.10) 3.62* 3.34-3.93 5149 10.17 (0.14) 4.56* 4.28-4.86
30-34 4223 7.66 (0.12) 5.52* 5.11-5.97 7185 13.30 (0.16) 5.97* 5.61-6.35
35-39 6490 11.07 (0.14) 7.97* 7.40-8.60 9193 15.75 (0.16) 7.06* 6.65-7.51
Diagnosis year
1999-2000 3862 5.62 (0.09) 0.94* 0.90-0.98 5993 8.85 (0.11) 0.91* 0.88-0.94
2001-2003 6121 6.00 (0.08) 1.00 e 9813 9.77 (0.10) 1.00 e
2004-2006 5694 5.64 (0.07) 0.94* 0.91-0.98 10,230 10.31 (0.10) 1.06* 1.03-1.09
Race/ethnicity
NHW 14,191 7.94 (0.07) 1.00 e 23,321 13.23 (0.09) 1.00 e
HW 392 0.95 (0.05) 0.12* 0.11-0.13 853 2.41 (0.08) 0.18* 0.17-0.20
Black 79 0.25 (0.03) 0.03* 0.03-0.04 125 0.37 (0.03) 0.03* 0.02-0.03
AI/AN 53 2.22 (0.31) 0.28* 0.21-0.37 74 2.89 (0.34) 0.22* 0.17-0.27
API 64 0.42 (0.05) 0.05* 0.04-0.07 117 0.73 (0.07) 0.05* 0.05-0.07
Data are from population-based cancer registries that participate in National Program of Cancer Registries and/or Surveillance Epidemiology
and End Results Program and meet high-quality data criteria. These registries cover 67.2% of population for 1999-2006.
Rates are per 100,000 population and are age-adjusted to 2000 US standard population.
AI/AN, American Indians/Alaska Natives; API, Asian Pacific Islanders; CI, confidence interval; HW, Hispanic white; NHW, non-Hispanic white; e,
not applicable.
*Rate ratio was statistically significantly different from 1.00 (2-sided P\.05).
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The most common site of diagnosis was trunk of
body for both males and females (46.7% and 36.8%,
respectively) followed by upper extremities in males
(18.2%) and lower extremities in females (31.4%)
(Table III). For melanomas of the face, head, and
neck, males had higher incidence rates compared
with females (0.92/100,000 vs 0.78/100,000, respec-
tively) with proportionately twice as many casesdiagnosed at this site in males (16.0%) compared
with females (8.0%).
Greater than 99% of all melanoma incident cases
(n = 41,549) were microscopically confirmed.
Among these cases, more than 53% of all cases
were reported as melanoma NOS (Histology NOS)
among males and females (53.5% and 53.2%, respec-
tively). Among those cases with a specific histologic
type reported, superficial spreading melanoma
Table III. Invasive melanoma incidence among adolescents and young adults (age 15-39 years) by tumor
characteristics and sex: United States 1999-2006
Male Female
No. Rate 95% CI No. Rate 95% CI
Primary site
Trunk 7317 (46.7%) 2.70 2.63-2.76 9570 (36.8%) 3.57 3.50-3.64
Upper extremities 2857 (18.2%) 1.05 0.02-1.02 5618 (21.6%) 2.11 2.05-2.15
Lower extremities 2296 (14.6%) 0.85 0.81-0.88 8181 (31.4%) 3.07 3.00-3.13
Face, head, and neck 2515 (16.0%) 0.92 0.88-0.96 2094 (8.0%) 0.78 0.75-0.82
NOS 692 (4.4%) 0.25 0.24-0.27 573 (2.2%) 0.21 0.20-0.23
Histopathology*
Superficial spreading 5456 (35.0%) 2.01 1.96-2.06 9904 (38.2%) 3.70 3.63-3.78
Nodular 955 (6.1%) 0.35 0.33-0.37 1085 (4.2%) 0.41 0.38-0.43
Lentigo maligna 133 (0.9%) 0.05 0.04-0.06 121 (0.5%) 0.05 0.04-0.05
Acral lentiginous 87 (0.6%) 0.03 0.0-0.04 135 (0.5%) 0.05 0.04-0.06
Other specified 623 (4.0%) 0.23 0.21-0.25 906 (3.5%) 0.34 0.32-0.36
NOS 8346 (53.5%) 3.07 3.01-3.14 13,798 (53.2%) 5.16 5.08-5.25
Stagey
Localized 4457 (78.3%) 4.42 4.29-4.55 8637 (84.4%) 8.71 8.53-8.89
Regional 639 (11.2%) 0.63 0.58-0.68 680 (6.6%) 0.69 0.63-0.74
Distant 191 (3.4%) 0.19 0.16-0.22 134 (1.3%) 0.14 0.11-0.16
NOS 407 (7.1%) 0.40 0.36-0.44 779 (7.6%) 0.78 0.73-0.84
Data are from population-based cancer registries that participate in National Program of Cancer Registries and/or Surveillance Epidemiology
and End Results Program and meet high-quality data criteria. These registries cover 67.2% of population for 1999-2006.
Rates are per 100,000 population and are age-adjusted to 2000 US standard population.
CI, Confidence interval; NOS, not otherwise specified.
*Histologically confirmed cases (n = 41,549).
yCases diagnosed 2004-2006.
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and females (35.0% and 38.2%, respectively) fol-
lowed by nodular melanoma (6.1% and 4.2%, re-
spectively). Lentigo maligna and acral lentiginous
melanoma each accounted for less than 1% of cases
among either males or females of all races and
ethnicities combined. Other specific histologic types
combined accounted for between 3% to 4% all cases
combined.
For patients given a diagnosis between 2004 and
2006, the majority of cases were diagnosed at a local
stage of disease (78.3% of males and 84.4% of
females) with proportionately more males than
females given a diagnosis of regional (11.2% vs
6.6%) and distant (3.4% and 1.3%) staged disease.
Tumor characteristics by race and ethnicity
Among adolescents and young adults, incidence
rates were highest among NHW compared with HW
and non-whites regardless of site, histology, and
stage (Table IV). Among males, the most common
site of diagnosis was trunk among all racial and
ethnic groups, followed by upper extremities in
NHW and HW and lower extremities among non-
whites (Fig 1, A). Face, head, and neck was the third
most common site among NHW males. Amongfemales, trunk of body was the most common site
of diagnosis among NHWwhereas lower extremities
was the most common site among HW and non-
whites (Fig 1, D). Conversely, the lower extremities
were the secondmost common site among NHWand
the trunk of the body was the second most common
site among non-white females. Upper extremities
were the third most common site among females of
all racial and ethnic groups.
Histology NOS was the most common histology
reporting among males and females of all racial and
ethnic groups, accounting for between 52% and 56%
of all cases combined (Table IV). Among males and
females of all racial and ethnic groups with a specific
histologic type reported, superficial spreading was
the most common followed by nodular melanoma
(Fig 1, B and E ). Lentigo maligna was rare among all
racial and ethnic groups accounting for less than 1%
of cases among NHW males and females. Acral
lentiginous melanomas were rare (0.5%) among
NHW males and females, and proportionately more
common among HW males and females (3.3% and
1.3%, respectively). Other specified histologic types
were reported to occur proportionately more fre-
quently among non-whites followed by HW and
NHW.
Table IV. Invasive melanoma incidence among adolescents and young adults (age 15-39 years) by tumor
characteristics, race and ethnicity, and sex: United States, 1999 through 2006
Non-Hispanic white Hispanic white Non-white (black, AI/AN, API)
Count Rate 95% CI Count Rate 95% CI Count Rate 95% CI
Male
Site
Trunk 6627 3.71 3.62-3.80 146 0.36 0.30-0.42 77 0.15 0.12-0.19
Upper extremities 2571 1.44 1.38-1.50 86 0.21 0.16-0.26 29 0.06 0.04-0.08
Lower extremities 2049 1.15 1.10-1.20 76 0.18 0.15-0.23 53 0.10 0.08-0.14
Face, head, and neck 2331 1.30 1.25-1.35 54 0.13 0.10-0.17 26 0.05 0.03-0.07
NOS 613 0.34 0.32-0.37 30 0.07 0.05-0.10 \16 e e
Histology
Superficial spreading 4998 2.80 2.72-2.88 109 0.26 0.21-0.32 42 0.08 0.06-0.11
Nodular 886 0.50 0.46-0.53 33 0.08 0.05-0.11 18 0.03 0.02-0.05
Lentigo maligna 123 0.07 0.06-0.08 \16 e e \16 e e
Acral lentiginous 64 0.04 0.03-0.05 \16 e e \16 e e
Other specified 555 0.31 0.28-0.34 27 0.07 0.04-0.10 18 0.03 0.02-0.05
NOS 7502 4.20 4.10-4.29 205 0.50 0.43-0.58 113 0.22 0.18-0.26
Stagey
Localized 4062 6.32 6.13-6.52 97 0.58 0.47-0.71 41 0.25 0.19-0.33
Regional and distant 762 1.18 1.10-1.27 36 0.21 0.15-0.30 23 0.13 0.08-0.19
NOS 336 0.52 0.47-0.58 \16 e e \16 e e
Female
Site
Trunk 8611 4.88 4.78-4.99 261 0.74 0.65-0.83 88 0.16 0.13-0.20
Upper extremities 5051 2.87 2.79-2.95 181 0.51 0.44-0.59 56 0.10 0.08-0.13
Lower extremities 7312 4.15 4.05-4.24 288 0.82 0.72-0.92 123 0.22 0.19-0.27
Face, head, and neck 1875 1.06 1.02-1.11 96 0.27 0.22-0.33 36 0.06 0.04-0.09
NOS 472 0.27 0.24-0.29 27 0.08 0.05-0.11 22 0.04 0.02-0.06
Histology*
Superficial spreading 8991 5.1 4.99-5.21 286 0.81 0.72-0.91 89 0.16 0.13-0.20
Nodular 995 0.56 0.53-0.60 39 0.11 0.07-0.14 20 0.04 0.02-0.06
Lentigo maligna 100 0.06 0.05-0.07 \16 e e \16 e e
Acral lentiginous 106 0.06 0.05-0.07 \16 e e \16 e e
Other specified 790 0.45 0.42-0.48 38 0.11 0.08-0.15 27 0.05 0.03-0.07
NOS 12227 6.96 6.83-7.08 476 1.35 1.23-1.48 171 0.31 0.26-0.36
Stagey
Localized 7788 12.21 11.94-12.49 278 1.97 1.75-2.22 88 0.41 0.33-0.51
Regional and distant 726 1.14 1.06-1.22 48 0.33 0.25-0.44 29 0.14 0.09-0.20
NOS 608 0.95 0.88-1.03 21 0.15 0.09-0.23 17 0.08 0.05-0.13
Data are from population-based cancer registries that participate in National Program of Cancer Registries and/or Surveillance Epidemiology
and End Results Program and meet high-quality data criteria. These registries cover 67.2% of population for 1999-2006.
Rates are per 100,000 population and are age-adjusted to 2000 US standard population. Rates were suppressed if case count was\16. Case
counts\16 were suppressed in tables but not in figures.
AI/AN, American Indians/Alaskan Natives; API, Asian Pacific Islanders; CI, confidence interval; NOS, not otherwise specified; e, rate or count
suppressed (see footnote).
*Histologically confirmed cases (n = 41,549).
yCases diagnosed 2004-2006.
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localized stage among males and females of all racial
and ethnic groups (Fig 1, C and F ). There were
proportionately more regional and distant staged
cancers diagnosed in HW males and females (25.0%
and 13.8%, respectively) and non-white males and
females (32.4% and 21.6%, respectively) compared
with NHW males and females (14.8% and 8.0%,
respectively).Site and histology among NHW
There were sufficient numbers of incident cases to
examine incidence patterns by histologic type and
site of diagnosis among NHW males and females
(Table V). Histology NOS was the most commonly
reported histologic type reported at all sites com-
bined in males and females, respectively (data not
shown), and occurred at site NOS in 90.3% and 87.3%
of cases amongmales and females, respectively (data
Fig 1. Distribution of invasive melanoma incident cases among adolescents and young adults
(age 15-39 years) by site (A andD), histology (B and E), stage (C and F), race and ethnicity (A to
F): United States 1999-2006. Data are from population-based cancer registries that participate in
National Program of Cancer Registries and/or Surveillance Epidemiology and End Results
Program and meet high-quality data criteria. These registries cover 67.2% of population for
1999-2006. Histology, not otherwise specified (NOS ) not included. Case counts less than 16 are
included. API, Asian Pacific Islanders; AI/AN, American Indians/Alaskan Natives.
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Weir et al S38.e8not shown). Among cases with a specific histology
reported, superficial spreading and nodular melano-
mas occurred at all body sites: trunk; upper extrem-
ities; lower extremities; and face, head, and neck
(Fig 2). Lentigo maligna melanoma and other spec-
ified histologic types were reported to occur pro-
portionately more often on the face, head, and neck.
Acral lentiginous melanoma was reported to occur
on the lower extremities of the body.
DISCUSSION
Melanoma is the second most commonly diag-
nosed cancer among adolescents and young adults in
the United States,1 although mortality continues to
decline as survival improves, particularly among ad-
olescents and young adults.4 The early age at onset of
these cancers suggests that early life factors are
important. InNHWinparticular,melanomasoccurring
in this age group may represent gene-environment
interactions involving excessive, intermittent UVR
exposure among susceptible individuals, whereaslate-onset melanomas may more often reflect accu-
mulated, lifelong sun exposures in comparatively less
susceptible individuals.30,31
The incidence of melanoma was higher in ado-
lescent and young adult females compared with
males in all age subgroups and in all racial and ethnic
groups examined. This pattern is consistent with
other published reports that have looked primarily at
melanoma within the NHW adolescent and young
adult populations,1 but differs from the pattern of
male excess seen at older ages.32 This reversal in the
gender RR between younger and older age groups
suggests that there may be differences between
etiologic pathways in younger versus older age
groups that are mediated by gender.
One factor that may be related to this observed
age-specific incidence pattern is female sex hor-
mones. Some studies have found that the use of oral
contraceptive or hormonal replacement therapy was
associated with an increased risk of melanoma,33,34
whereas other studies have not found an
Table V. Invasive melanoma incidence among non-Hispanic white adolescents and young adults (age 15-39
years) by site, histology, and sex: United States, 1999 through 2006
Trunk Upper extremities Lower extremities Face, head, and neck
Count Rate 95% CI Count Rate 95% CI Count Rate 95% CI Count Rate 95% CI
Male
Superficial spreading 2590 1.45 1.39-1.51 926 0.52 0.49-0.55 717 0.40 0.37-0.43 738 0.41 0.38-0.44
Nodular 378 0.21 0.19-0.23 191 0.11 0.09-0.12 136 0.08 0.06-0.09 176 0.10 0.08-0.11
Lentigo maligna 28 0.02 0.01-0.02 \16 e e \16 e e 76 0.04 0.03-0.05
Acral lentiginous \16 e e \16 e e 49 0.03 0.02-0.04 \16 e e
Other specified 241 0.13 0.12-0.15 90 0.05 0.04-0.06 68 0.04 0.03-0.05 132 0.07 0.06-0.09
NOS 3375 1.89 1.83-1.95 1336 0.75 0.71-0.79 1069 0.60 0.56-0.64 1203 0.67 0.63-0.71
Female
Superficial spreading 3500 1.98 1.92-2.05 1956 1.11 1.06-1.16 2861 1.62 1.56-1.68 640 0.36 0.34-0.39
Nodular 308 0.17 0.16-0.20 260 0.15 0.13-0.17 322 0.18 0.16-0.20 102 0.06 0.05-0.07
Lentigo maligna 27 0.02 0.01-0.02 \16 e e \16 e e 44 0.02 0.02-0.03
Acral lentiginous \16 e e \16 e e 90 0.05 0.04-0.06 0 0 e
Other specified 312 0.18 0.16-0.20 165 0.09 0.08-0.11 192 0.11 0.09-0.13 103 0.06 0.05-0.07
NOS 4449 2.52 2.45-2.60 2634 1.49 1.44-1.55 3820 2.17 2.10-2.24 980 0.56 0.52-0.59
Histologically confirmed cases only (n = 41,549).
Data are from population-based cancer registries that participate in National Program of Cancer Registries and/or Surveillance Epidemiology
and End Results Program and meet high-quality data criteria. These registries cover 67.2% of population for 1999-2006.
Rates are per 100,000 population and are age-adjusted to 2000 US standard population. Rates and counts were suppressed if case count was
\16. Case counts[1 and\16 were suppressed in tables.
CI, Confidence interval; NOS, not otherwise specified; e, rate or count suppressed (see footnote).
Fig 2. Distribution of histologically confirmed invasive melanoma incident cases among non-
Hispanic white adolescents and young adults (age 15-39 years) by site and histology (other
than not otherwise specified [NOS]): United States 1999-2006. A, Males. B, Females. Data are
from population-based cancer registries that participate in National Program of Cancer
Registries and/or Surveillance Epidemiology and End Results Program and meet high-quality
data criteria. These registries cover 67.2% of population for 1999-2006. Histology NOS not
included. Case counts less than 16 are included.
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related to variations in measurement of estrogen
receptor expressions.37 Specific genotypes have
been found to be related to increased risk of mela-
noma among young women and may play a crucial
role in the development of melanoma.38 In addition,
one case-control study has suggested a link between
endogenous female hormones related to pregnancy
and increased melanoma risk.35 Additional research
is needed to further explore possible etiologic path-
ways and the relationship between longitudinal
trends in incidence and fertility rates (ie, delayed
childbearing age at first birth and number of full term
pregnancies).39This study, although limited in years of observa-
tion, found evidence that incidence rates increased
over time among adolescent and young adult fe-
males but not males. This finding is consistent with
the results from previous studies based on data from
the SEER Program, covering between 10% to 14% of
the US population.4-6,32 There was a steeper increase
in incidence among young females than males and
mortality decreased in both groups. An increase in
the incidence of melanoma in the presence of
declining mortality could be explained by expanded
skin screening and detection of biologically indolent
tumors with low metastatic potential. However, an
analysis of SEER incidence data over a 10-year period
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occurred in all socioeconomic groups, histologic
subtypes, and tumor thickness. The authors con-
cluded that screening associated diagnoses could not
explain the increasing incidence of thicker tumors in
lower socioeconomic groups with poorer access to
screening.40
Historical data on sun exposure in the United
States by age are limited. However, one study
reported an increase (although not statistically sig-
nificant) in prevalence of sunburn in age 16 to 18
years from 1998 to 2004.41 Further, the prevalence of
sunburn at all ages has continued to increase in both
men and women.42 Sunburn has typically been used
as one indicator of high intermittent exposure to
UVR, the form of sun exposure most strongly related
to melanoma risk.13
In addition, there is increasing evidence that
artificial sources of UV exposure, including frequent
indoor tanning, are associated with melanoma and
other skin cancers.12,43,44 Adolescents, especially
white adolescent girls, commonly use indoor tan-
ning: up to 37% of NHW female adolescents and 11%
of NHW male adolescents have used tanning booths
at least once in their lifetimes45,46 and approximately
11% of adolescents report using a tanning bed in the
past year.41,47,48 Certain segments of the population,
especially teenagers and young adults, view the
purported benefits of UV exposure (eg, protective
base tan, appearances, feel healthy, and social
interactions with friends) as outweighing the risk
for skin cancer and effects on their future appearance
(wrinkles).49-54 These attitudes are also associated
with sporadic sunscreen use and more frequent
sunburns.48
In general, melanoma is uncommon in non-
whites and Hispanics when compared with NHW
populations of all ages.55 The low incidence of skin
cancers in darker-skinned groups is primarily a result
of photoprotection provided by increased epidermal
melanin, which filters twice as much UVR as does
that in the epidermis of whites.56 Hence, UVR, the
most important predisposing factor for skin cancer in
whites, appears to play a lesser role in darker-
skinned individuals.
The body site distribution of melanoma in
adolescents and young adults differ somewhat
from that of older adults. In both sexes, melanomas
of the trunk are overrepresented in adolescents and
young adults compared with older adults.55 The
preponderance of trunk melanomas in this age
groupeaccounting for nearly half (46.7%) of mela-
nomas in males and 37% in femalesesuggests the
importance of intermittent sun exposure, because
the trunk is considered a usually unexposed bodysite, with most exposure in short, intense bursts. The
variation in body site distribution across racial/ethnic
groups parallels that for all ages, with melanomas on
the lower extremities relatively more common in HW
and non-white racial groups.55,57
Among the 4 specified histologic types of mela-
noma, superficial spreading melanoma and nodular
melanoma account for the majority of lesions in
adolescents and young adults, and occurred in all
sites of the body among NHW. This is consistent with
other studies that have reported superficial spread-
ing melanomas to be more common among whites
and Hispanics.58 Although the numbers are too small
to draw any conclusions from these data about
differences in the distribution of histologic types
across racial/ethnic groups in adolescents and young
adults, there is a suggestion that groups other than
NHW have an overrepresentation of acral lentigi-
nous melanomas and other specified histologies.
This is consistent with findings for all ages that acral
lentiginous melanomas, which usually arise on the
palm of the hand or sole of the foot, is more common
in people of color, especially blacks, compared with
white populations.57,59 This observation probably
accounts, at least in part, for the excess of melano-
mas on the lower extremities observed in these
groups. In addition, in whites and to a lesser extent,
Hispanics, melanomas predominantly occur in sun-
exposed skin, whereas in Asians and blacks, UV does
not appear to be a significant risk factor, and the
majority occurs in non-sun-exposed skin.60
Strengths and limitations
Understanding the burden and relative risk of
melanoma among adolescents and young adults is
important to developing effective and targeted ap-
proaches to reducing incidence and deaths. This
study provides a detailed description of melanoma
incidence by demographic and tumor characteristics
among patients between the ages of 15 to 39 years
using data from38 population-based cancer registries
participating in either or both the NPCR and SEER
Program and covering 67.2% of the US population.
Population-based cancer registries provide critical
information on the cancer burden and the United
States is fortunate to have nearly nationwide cancer
surveillance coverage. We used only high-quality
registry data to mitigate the influence of the under-
reporting of incidence cases and themisclassification
of demographic and tumor-related data. However,
this study is subject to several limitations.
First, incomplete reporting and misclassification
of data remain a potential problem in cancer regis-
tries. As this study reported, up to 6% cases had
unspecified or unknown race/ethnicity data. And
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the systematic underreporting of cancer in the AI/AN
population.61 Routine linkage of cancer registry data
with Indian Health Service administrative databases
for the purpose of classifying race and improved
collection and reporting of race information in pop-
ulation estimates26 has resulted in a more accurate
estimate of the cancer burden in the AI/AN popula-
tion,61 including melanomas in AI/AN adolescents
and young adults.62,63 Second, more than 50% of all
cases were codedwith aHistology NOS, thus limiting
our ability to lookmore closely at histologic subtypes
including ‘‘other’’ specific histologic types that may
differ by age, race, and ethnicity. Primary data
reporters (physicians, and laboratory and medical
records staff) play a critical role in the ability of the
cancer registry staff to collect, consolidate, and
report complete, accurate, and specific incidence
data. Improved primary data reporting is needed to
increase data specificity in the future.
Public health implications
There are important reasons for examining the
cancer burden in adolescents and young adults. An
examination of incidence patterns in this age group
may foretell the future cancer burden, because
changing exposure opportunities of early life that
can begin to manifest as cancer during adolescence
and young adulthood, and provide insight into
etiologic relationships as the time since exposure
and diagnosis may be somewhat shorter in young
adults than for older adults.7,62 In particular, an
analysis of melanoma among the young adult pop-
ulation may provide insight into the current and
future burden of melanoma in the US population and
serve as a critical first step toward describing, mon-
itoring, and eventually eliminating this cancer.
Public health campaigns to promote awareness of
the risk of sun exposure in Australia and Europe may
have contributed to stabilizing or declining mela-
noma incidence rates in young adults in those
countries. There is increasing awareness of the
potential harmful effects of artificial sources of UV
exposure particularly among adolescents and young
adults. The World Health Organization has desig-
nated tanning equipment to be carcinogenic.44 As of
June 2011, 26 states had enacted laws restricting
minors access to tanning facilities.63
Promoting awareness of the harmful effects of UV
exposure (both artificial and natural) and promoting
screening for melanoma remain important strategies
for reducing the future burden of melanoma in the
adolescent and young adult populations. In addition,
additional research is required to understand the role
of gene-environment exposure interaction and to beable to identify susceptible individuals in the popu-
lations that may be at particular risk of developing
melanoma.
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